Kevin C. Ma, D. Surie, A. Lauring, Mph Emily T. Martin PhD, Aleda M Leis, Leigh Papalambros Mph, Manjusha Gaglani Mbbs, Christie Columbus, Robert L Gottlieb, S. Ghamande, MSc Ithan D. Peltan MD, Samuel M. Brown, A. Ginde, Nicholas M. Mohr, K. Gibbs, David N. Hager, Safa Saeed Mbbs, M. Prekker, M. Gong, Amira Mohamed, N. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Akram Khan Mbbs, Catherine L. Hough, Abhijit Duggal, Jennifer G. Wilson, N. Qadir, PhD Steven Y. Chang MD, Christopher Mallow, Msci Jennie H. Kwon DO, Bijal Parikh, Mph Ivana A. Vaughn PhD, Mayur Ramesh, MSc Basmah Safdar MD, J. Mosier, Estelle S. Harris, Nathan I. Shapiro, Mph Jamie Felzer MD, Yuwei Zhu, Mph Carlos G Grijalva MD, Natasha Halasa, James D. Chappell, K. Womack, J. Rhoads, A. Baughman, S. Swan, 27 Mph, MS CassandraA.Johnson, MSc Todd W. Rice MD, Jonathan D. Casey, Mhs Paul W. Blair MD, MSc Jin H. Han MD, Sascha Ellington, Nathaniel M Lewis, Natalie Thornburg, Clinton R. Paden, PhD Lydia J. Atherton DVM, Mph Wesley H. Self MD, F.
{"title":"2023-2024 年更新版(单价 XBB.1.5)COVID-19 疫苗对 SARS-CoV-2 Omicron XBB 和 BA.2.86/JN.1 系住院治疗的效果以及临床严重程度的比较 -- IVY 网络,26 家医院,2023 年 10 月 18 日-2024 年 3 月 9 日","authors":"Kevin C. Ma, D. Surie, A. Lauring, Mph Emily T. Martin PhD, Aleda M Leis, Leigh Papalambros Mph, Manjusha Gaglani Mbbs, Christie Columbus, Robert L Gottlieb, S. Ghamande, MSc Ithan D. Peltan MD, Samuel M. Brown, A. Ginde, Nicholas M. Mohr, K. Gibbs, David N. Hager, Safa Saeed Mbbs, M. Prekker, M. Gong, Amira Mohamed, N. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Akram Khan Mbbs, Catherine L. Hough, Abhijit Duggal, Jennifer G. Wilson, N. Qadir, PhD Steven Y. Chang MD, Christopher Mallow, Msci Jennie H. Kwon DO, Bijal Parikh, Mph Ivana A. Vaughn PhD, Mayur Ramesh, MSc Basmah Safdar MD, J. Mosier, Estelle S. Harris, Nathan I. Shapiro, Mph Jamie Felzer MD, Yuwei Zhu, Mph Carlos G Grijalva MD, Natasha Halasa, James D. Chappell, K. Womack, J. Rhoads, A. Baughman, S. Swan, 27 Mph, MS CassandraA.Johnson, MSc Todd W. Rice MD, Jonathan D. Casey, Mhs Paul W. Blair MD, MSc Jin H. Han MD, Sascha Ellington, Nathaniel M Lewis, Natalie Thornburg, Clinton R. Paden, PhD Lydia J. Atherton DVM, Mph Wesley H. Self MD, F. ","doi":"10.1101/2024.06.04.24308470","DOIUrl":null,"url":null,"abstract":"Background: Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as \"JN lineages\"), emerged in late 2023 and exhibited substantial genomic divergence from co-circulating XBB lineages. Methods: We analyzed patients hospitalized with COVID-19-like illness at 26 hospitals in 20 U.S. states admitted October 18, 2023-March 9, 2024. Using a test-negative, case-control design, we estimated the effectiveness of an updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine dose against sequence-confirmed XBB and JN lineage hospitalization using logistic regression. Odds of severe outcomes, including intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) or death, were compared for JN versus XBB lineage hospitalizations using logistic regression. Results: 585 case-patients with XBB lineages, 397 case-patients with JN lineages, and 4,580 control-patients were included. VE in the first 7-89 days after receipt of an updated dose was 54.2% (95% CI = 36.1%-67.1%) against XBB lineage hospitalization and 32.7% (95% CI = 1.9%-53.8%) against JN lineage hospitalization. Odds of ICU admission (adjusted odds ratio [aOR] 0.80; 95% CI = 0.46-1.38) and IMV or death (aOR 0.69; 95% CI = 0.34-1.40) were not significantly different among JN compared to XBB lineage hospitalizations. Conclusions: Updated 2023-2024 COVID-19 vaccination provided protection against both XBB and JN lineage hospitalization, but protection against the latter may be attenuated by immune escape. Clinical severity of JN lineage hospitalizations was not higher relative to XBB lineage hospitalizations.","PeriodicalId":506788,"journal":{"name":"medRxiv","volume":"12 36","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity -- IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024\",\"authors\":\"Kevin C. Ma, D. Surie, A. Lauring, Mph Emily T. Martin PhD, Aleda M Leis, Leigh Papalambros Mph, Manjusha Gaglani Mbbs, Christie Columbus, Robert L Gottlieb, S. Ghamande, MSc Ithan D. Peltan MD, Samuel M. Brown, A. Ginde, Nicholas M. Mohr, K. Gibbs, David N. Hager, Safa Saeed Mbbs, M. Prekker, M. Gong, Amira Mohamed, N. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Akram Khan Mbbs, Catherine L. Hough, Abhijit Duggal, Jennifer G. Wilson, N. Qadir, PhD Steven Y. Chang MD, Christopher Mallow, Msci Jennie H. Kwon DO, Bijal Parikh, Mph Ivana A. Vaughn PhD, Mayur Ramesh, MSc Basmah Safdar MD, J. Mosier, Estelle S. Harris, Nathan I. Shapiro, Mph Jamie Felzer MD, Yuwei Zhu, Mph Carlos G Grijalva MD, Natasha Halasa, James D. Chappell, K. Womack, J. Rhoads, A. Baughman, S. Swan, 27 Mph, MS CassandraA.Johnson, MSc Todd W. Rice MD, Jonathan D. Casey, Mhs Paul W. Blair MD, MSc Jin H. Han MD, Sascha Ellington, Nathaniel M Lewis, Natalie Thornburg, Clinton R. Paden, PhD Lydia J. Atherton DVM, Mph Wesley H. Self MD, F. \",\"doi\":\"10.1101/2024.06.04.24308470\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as \\\"JN lineages\\\"), emerged in late 2023 and exhibited substantial genomic divergence from co-circulating XBB lineages. Methods: We analyzed patients hospitalized with COVID-19-like illness at 26 hospitals in 20 U.S. states admitted October 18, 2023-March 9, 2024. Using a test-negative, case-control design, we estimated the effectiveness of an updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine dose against sequence-confirmed XBB and JN lineage hospitalization using logistic regression. Odds of severe outcomes, including intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) or death, were compared for JN versus XBB lineage hospitalizations using logistic regression. Results: 585 case-patients with XBB lineages, 397 case-patients with JN lineages, and 4,580 control-patients were included. VE in the first 7-89 days after receipt of an updated dose was 54.2% (95% CI = 36.1%-67.1%) against XBB lineage hospitalization and 32.7% (95% CI = 1.9%-53.8%) against JN lineage hospitalization. Odds of ICU admission (adjusted odds ratio [aOR] 0.80; 95% CI = 0.46-1.38) and IMV or death (aOR 0.69; 95% CI = 0.34-1.40) were not significantly different among JN compared to XBB lineage hospitalizations. Conclusions: Updated 2023-2024 COVID-19 vaccination provided protection against both XBB and JN lineage hospitalization, but protection against the latter may be attenuated by immune escape. Clinical severity of JN lineage hospitalizations was not higher relative to XBB lineage hospitalizations.\",\"PeriodicalId\":506788,\"journal\":{\"name\":\"medRxiv\",\"volume\":\"12 36\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.06.04.24308470\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.06.04.24308470","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity -- IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024
Background: Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as "JN lineages"), emerged in late 2023 and exhibited substantial genomic divergence from co-circulating XBB lineages. Methods: We analyzed patients hospitalized with COVID-19-like illness at 26 hospitals in 20 U.S. states admitted October 18, 2023-March 9, 2024. Using a test-negative, case-control design, we estimated the effectiveness of an updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine dose against sequence-confirmed XBB and JN lineage hospitalization using logistic regression. Odds of severe outcomes, including intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) or death, were compared for JN versus XBB lineage hospitalizations using logistic regression. Results: 585 case-patients with XBB lineages, 397 case-patients with JN lineages, and 4,580 control-patients were included. VE in the first 7-89 days after receipt of an updated dose was 54.2% (95% CI = 36.1%-67.1%) against XBB lineage hospitalization and 32.7% (95% CI = 1.9%-53.8%) against JN lineage hospitalization. Odds of ICU admission (adjusted odds ratio [aOR] 0.80; 95% CI = 0.46-1.38) and IMV or death (aOR 0.69; 95% CI = 0.34-1.40) were not significantly different among JN compared to XBB lineage hospitalizations. Conclusions: Updated 2023-2024 COVID-19 vaccination provided protection against both XBB and JN lineage hospitalization, but protection against the latter may be attenuated by immune escape. Clinical severity of JN lineage hospitalizations was not higher relative to XBB lineage hospitalizations.